logo-loader
viewGenprex, Inc.

Genprex reveals slew of recent milestones as it plans for upcoming clinical trials

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates.

Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What's more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.

Quick facts: Genprex, Inc.

Price: 3.56 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $137.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex forms global licensing deal with MD Anderson for its cancer drug...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the group has been awarded a worldwide license, allowing it to use lead candidate Oncoprex to treat cancer in combination with a range of immunotherapies. Varner says it means Genprex can now use its TUSC2 gene therapy in combination...

on 05/14/2020

2 min read